stockrowKorsana Biosciences, Inc.
KRSA Healthcare Biotechnology
- Revenue
- −43.2%
- EPS
- −272.7%
- Free cash flow
- −184.7%
Quarter to June 2026, against a year earlier
Follow KRSA
Alert me
Korsana Biosciences, Inc. (KRSA) EV/Sales
As of 6 November 2026, Korsana Biosciences, Inc. (KRSA) trades at a EV/Sales of 8.3×. Over the past ten years it has ranged from −4.5× (June 2022) to 78.0× (June 2021); the current reading is higher than 79% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.4× | (76.92%) |
| FY2024 | 1.7× | (77.05%) |
| FY2022 | 7.3× | 114.77% |
| FY2021 | 3.4× | (79.82%) |
| FY2020 | 16.8× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 0.4× | (61.33%) |
| Sep 2025 | 1.0× | (63.39%) |
| Jun 2025 | 2.7× | 166.46% |
| Mar 2025 | 1.0× | (38.82%) |
| 16 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | n/m |
| MLYS Mineralys Therapeutics, Inc. compare | n/m |
| TYRA Tyra Biosciences, Inc. compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR compare | n/m |
| DMRA Galecto, Inc. compare | n/m |
| ANAB AnaptysBio, Inc. compare | 4.5× |
| KRSA Korsana Biosciences, Inc. | 8.3× |
| OCUL Ocular Therapeutix, Inc. compare | 18.5× |
| TSHA Taysha Gene Therapies, Inc. compare | 102× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)